JESSICA MULCAHY: Open Payments
NPI 1053883645 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,055 in 59 payments from 12 companies in 2025. Trend: 2023 $818 · 2024 $688 · 2025 $1,055
Food & beverage: $1,055
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 16 | $266 |
| ABBVIE INC. | 15 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $188 |
| GENZYME CORPORATION | 3 | $83 |
| Phathom Pharmaceuticals, Inc. | 7 | $68 |
| Janssen Biotech, Inc. | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Ardelyx, Inc. | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $18 |
Products named: REZDIFFRA, EOHILIA, RINVOQ, DUPIXENT, VOQUEZNA, TREMFYA, LINZESS, IBSRELA.
Industry payments across NE — which companies pay providers there.
